TY - JOUR
T1 - How genomics can be used to understand host susceptibility to enteric infection, aiding in the development of vaccines and immunotherapeutic interventions
AU - Mottram, L.
AU - Chakraborty, Subhra
AU - Cox, Eric
AU - Fleckenstein, J.
N1 - Funding Information:
We thank Dr Susannah Leach of the University of Gothenburg, Sweden for transcribing during this VASE workshop. The work described by Mottram's research in this publication was funded by the Swedish Research Council (grants 2013-6615 and 2011-3435) and the Swedish Strategic Foundation (grant SB12-0072). Dr Fleckenstein's research in this publication was supported in part by PATH, funding from National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers R01AI089894, R01AI126887 (jmf), the Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences (NCATS) of the NIH, and the Department of Veterans Affairs (5I01BX001469, jmf). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NIAID, NCATS, the Department of Veterans Affairs, or PATH. The last author Dr Fleckenstein is listed as an inventor on the patent 8,323,668 related to the EtpA protein.
Funding Information:
We thank Dr Susannah Leach of the University of Gothenburg , Sweden for transcribing during this VASE workshop. The work described by Mottram’s research in this publication was funded by the Swedish Research Council (grants 2013-6615 and 2011-3435 ) and the Swedish Strategic Foundation (grant SB12-0072 ). Dr Fleckenstein’s research in this publication was supported in part by PATH , funding from National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers R01AI089894 , R01AI126887 (jmf), the Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences (NCATS) of the NIH , and the Department of Veterans Affairs ( 5I01BX001469 , jmf). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH , NIAID , NCATS , the Department of Veterans Affairs, or PATH .
Funding Information:
We thank Dr Susannah Leach of the University of Gothenburg, Sweden for transcribing during this VASE workshop. The work described by Mottram's research in this publication was funded by the Swedish Research Council (grants 2013-6615 and 2011-3435) and the Swedish Strategic Foundation (grant SB12-0072). Dr Fleckenstein's research in this publication was supported in part by PATH, funding from National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers R01AI089894, R01AI126887 (jmf), the Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences (NCATS) of the NIH, and the Department of Veterans Affairs (5I01BX001469, jmf). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NIAID, NCATS, the Department of Veterans Affairs, or PATH.
Publisher Copyright:
© 2019 The Authors
PY - 2019/8/7
Y1 - 2019/8/7
N2 - Thanks to the modern sequencing era, the extent to which infectious disease imposes selective pressures on the worldwide human population is being revealed. This is aiding our understanding of the underlying immunological and host mechanistic defenses against these pathogens, as well as potentially assisting in the development of vaccines and therapeutics to control them. As a consequence, the workshop “How genomics can be used to understand host susceptibility to enteric infection, aiding in the development of vaccines and immunotherapeutic interventions” at the VASE 2018 meeting, aimed to discuss how genomics and related tools could be used to assist Shigella and ETEC vaccine development. The workshop featured four short presentations which highlighted how genomic applications can be used to assist in the identification of genetic patterns related to the virulence of disease, or host genetic factors that could contribute to immunity or successful vaccine responses. Following the presentations, there was an open debate with workshop attendees to discuss the best ways to utilise such genomic studies, to improve or accelerate the process of both Shigella and ETEC vaccine development. The workshop concluded by making specific recommendations on how genomic research methods could be strengthened and harmonised within the ETEC and Shigella research communities.
AB - Thanks to the modern sequencing era, the extent to which infectious disease imposes selective pressures on the worldwide human population is being revealed. This is aiding our understanding of the underlying immunological and host mechanistic defenses against these pathogens, as well as potentially assisting in the development of vaccines and therapeutics to control them. As a consequence, the workshop “How genomics can be used to understand host susceptibility to enteric infection, aiding in the development of vaccines and immunotherapeutic interventions” at the VASE 2018 meeting, aimed to discuss how genomics and related tools could be used to assist Shigella and ETEC vaccine development. The workshop featured four short presentations which highlighted how genomic applications can be used to assist in the identification of genetic patterns related to the virulence of disease, or host genetic factors that could contribute to immunity or successful vaccine responses. Following the presentations, there was an open debate with workshop attendees to discuss the best ways to utilise such genomic studies, to improve or accelerate the process of both Shigella and ETEC vaccine development. The workshop concluded by making specific recommendations on how genomic research methods could be strengthened and harmonised within the ETEC and Shigella research communities.
KW - ETEC
KW - Genomics
KW - Host genetic factors
KW - Host-pathogen interactions
KW - Shigella
KW - Vaccine antigen candidates
UR - http://www.scopus.com/inward/record.url?scp=85060657659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060657659&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2019.01.016
DO - 10.1016/j.vaccine.2019.01.016
M3 - Article
C2 - 30709726
AN - SCOPUS:85060657659
SN - 0264-410X
VL - 37
SP - 4805
EP - 4810
JO - Vaccine
JF - Vaccine
IS - 34
ER -